Gliomatosis cerebri classification: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 18: | Line 18: | ||
Type 1 (Primary) | Type 1 (Primary) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*No pre-existing primary cerebral neoplastic lesion (''de novo'') | |||
*No discrete mass | *No discrete mass | ||
*More common | *More common | ||
|- | |- | ||
Line 25: | Line 26: | ||
Type 2 (Secondary) | Type 2 (Secondary) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Results from a pre-existing cerebral glioma | |||
*Discrete mass with diffuse [[CNS]] involvement | *Discrete mass with diffuse [[CNS]] involvement | ||
*Less common | *Less common | ||
*''IDH1'' mutation is more common in this subtype | *''IDH1'' mutation is more common in this subtype |
Revision as of 18:22, 30 September 2015
Gliomatosis cerebri Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Gliomatosis cerebri classification On the Web |
American Roentgen Ray Society Images of Gliomatosis cerebri classification |
Risk calculators and risk factors for Gliomatosis cerebri classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Classification
Based on the origin
Gliomatosis cerebri may be classified into two subtypes:[1][2]
Type of gliomatosis cerebri | Characteristic features |
---|---|
Type 1 (Primary) |
|
Type 2 (Secondary) |
|
Based on the type of tumor cell
Gliomatosis cerebri may be classified based on the predominant tumor cell type into three subtypes:
- Astrocytic
- Oligodendroglial
- Mixed
References
- ↑ Classification of gliomatosis cerebri. Dr Henry Knipe and Dr Frank Gaillard et al. Radiopaedia 2015. http://radiopaedia.org/articles/gliomatosis-cerebri
- ↑ Brandão RA, de Carvalho GT, de Azeredo Coutinho CA, Christo PP, Santiago CF, Santos Mdo C; et al. (2011). "Gliomatosis cerebri: diagnostic considerations in three cases". Neurol India. 59 (1): 122–5. doi:10.4103/0028-3886.76892. PMID 21339680.